DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Stintzing S, Jung L, Rossius DP. et al.
Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
J Clin Oncol 2014
32. Suppl 03; abstract 445
We do not assume any responsibility for the contents of the web pages of other providers.